Home » Newsletters » BioWorld Science

BioWorld Science

Jan. 15, 2021

View Archived Issues

Omega selects OTX-2002 as development candidate for MYC-driven HCC

Chi3l1/YKL-40 as therapeutic target to slow the progression of AD

Positive interim data from controlled study of KB-109 in outpatients with COVID-19

FDA clears IND application for phase I/IIa study of VOR-33 in AML

First patient enrolled in phase IIb VISTAS study of volixibat in adults with PSC

CanSino Biologics patents glycoconjugates as vaccines for pneumococcal infections

Array BioPharma discloses BRAF mutant inhibitors

IL-37 and IL-1R8 deficiencies contribute to the pathogenesis of necrotizing enterocolitis

Binding of NAD+ to the ARM domain in SARM1 self-inhibits SARM1 to avoid axonal degeneration

Investigators present new antibodies for malaria

Japanese researchers propose Lister hooded rats as a new model of ADHD

Chinese approval of Rykindo for schizophrenia and psychotic states

CJ-2360 achieves complete tumor regression in ALK-positive xenografts

Bimagrumab improves traits in patients with type 2 diabetes and obesity

Glutamine aids and abets senescent cell survival

New classification scheme for glioblastomas

Mis-spliced RNAs in tumor cells trigger antiviral response

PW-0787, a novel potent and brain-penetrant GPR52 agonist for neuropsychiatric disorders

FDA approves Xalkori for ALK-positive ALCL in children and young adults

PK/PD effect studies evaluating differences in clinical efficacy of LEO-29102 and LEO-39652

Phase I/II results for COVID-19 vaccine Ad26.COV2.S support its further development

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 3, 2026.
ASCO 2026: A revolution in pancreatic cancer
BioWorld
At the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting, Revolution Medicines Inc. followed up its stellar top-line data with the details from the...
News in brief
BioWorld Asia
BioWorld Asia briefs for June 2, 2026
EASL 2026: Emerging liver disease targets to watch
BioWorld
At the recently concluded European Association for the Study of the Liver meeting, presentations underscored how increasingly granular insights into liver...
ASCO 2026: PD-(L)1 x VEGF bispecifics fight it out
BioWorld
Multiple companies are chasing Akeso Inc. and Summit Therapeutics Inc. in the battle to potentially dethrone Keytruda (pembrolizumab, Merck & Co. Inc.) as the top...